Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
The summary for the Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.
Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional: The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.
Federal Grant Title: | Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional |
Federal Agency Name: | Food and Drug Administration (HHS-FDA) |
Grant Categories: | Agriculture Consumer Protection Food and Nutrition |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-FD-24-006 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.103 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | March 31st, 2024 |
Original Application Deadline: | March 31st, 2024 |
Posted Date: | January 15th, 2024 |
Creation Date: | January 15th, 2024 |
Archive Date: | April 30th, 2024 |
Total Program Funding: | $300,000 |
Maximum Federal Grant Award: | $300,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | 2 |
Cost Sharing or Matching: | No |
Last Updated: | January 15th, 2024 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Unrestricted (i.e., open to any type of entity below), subject to any clarification in text field entitled "Additional Information on Eligibility"
- Grant Announcement Contact
- Terrin Brown
Grantor
Phone 2404027610
[email protected] - Similar Government Grants
- • Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical T...
- • Single Source Cooperative Agreement to Support HPAI H5N1 Research at Cornell University (U...
- • Animal and Veterinary Innovation Centers (U18)
- • Cooperative Agreement to Support the Illinois Institute of Technology's Institute for Food...
- • Minor Use Minor Species Development of Drugs (R01)
- • Support for Small Scientific Conference Grant Program
- • Cooperative Agreement to Support the World Health Organization (WHO) International Program...
- • Clinical Studies of Safety and Effectiveness of Orphan Products
- More Grants from the Food and Drug Administration
- • Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical T...
- • Single Source Cooperative Agreement to Support HPAI H5N1 Research at Cornell University (U...
- • Animal and Veterinary Innovation Centers (U18)